FOXP3 and systemic lupus erythematosus: This confluence of actions from diverse components targeting DNMT1 activity, Foxp3 expression, Treg function, and Th17 polarization collectively underpins the ability of JPZS to rectify the Treg/Th17 imbalance and ameliorate SLE pathology in the MRL/lpr model.